AngioDynamics, Inc.

NASDAQ:ANGO

Medical - Instruments & Supplies

Healthcare
$11.32 +1.71%

+$0.20 today

Market cap
$476.06M
Beta
0.36
P/E (TTM)
-15.8
EPS (TTM)
-$0.75
52W Low $8.36High $13.99

Volume 0.32M

Average 0.40M

ANGO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

AngioDynamics, Inc.NASDAQ: ANGO

Selling, General & Admin · Q3 FY2026 · quarter ended Feb 2026

Selling, general & admin grows in line with its trailing trend

Q3 FY2026 selling, general & admin of $38.16M rose 6.0% year over year, in line with the +6.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Selling, general & admin amounted to 49.7% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $145.11M (-0.1%) for the fiscal year ending May 2026, a pace similar to FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterFeb 2026
$38.16M+3.5% QoQ
Last fiscal yearMay 2025
$145.23M+0.9% YoY
LTMFeb 2026
$152.38M+6.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.0%-2.8%-8.8 pp
1 year+0.9%-0.1%-0.9 pp
3-year CAGR+2.8%+4.2%+1.4 pp
5-year CAGR+4.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
145.23M USD
Year-over-year change
+0.9%
4-year CAGR
+5.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ANGO compares with its peers on the latest reported figures

  • ANGO's LTM Feb 2026 selling, general & admin of $152.38M is the 8th highest of the 9 companies compared; the peer median is $718.87M.
  • Its year-over-year change of +6.1% is the 5th highest of 9, against a peer median of +7.3%.
  • Selling, general & admin amounts to 48.6% of revenue for ANGO, versus a peer median of 37.2%.
ANGO Competitors Peer median
Selling, General & Admin for ANGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BSXBoston Scientific CorporationLTM Jun 2026$7.16B +10.4%+15.1%34.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$5.17B -2.1%+1.7%25.6%
TFXTeleflex IncorporatedLTM Jun 2026$943.66M +0.4%-5.9%36.3%
PENPenumbra, Inc.LTM Jun 2026$741.31M +23.3%+13.8%49.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$696.44M -4.9%+4.3%42.3%
CNMDCONMED CorporationLTM Mar 2026$522.58M +4.9%+5.2%38.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$481.78M +9.7%+9.9%29.9%
ANGOAngioDynamics, Inc.LTM Feb 2026$152.38M +6.1%+2.8%48.6%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$98.35M +13.1%+16.1%38.4%
Peer median (excluding ANGO) $718.87M+7.3%+7.6%37.2%

Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue291.01M316.22M338.75M303.91M292.5M
Cost of Revenue134.22M150.49M164.51M149.22M134.79M
Gross Profit156.79M165.73M174.25M154.7M157.71M
Gross Margin53.9%52.4%51.4%50.9%53.9%
Research & Development36.39M30.74M29.88M31.51M26.22M
Selling, General & Admin117.22M133.75M144.25M143.98M145.23M
Operating Expenses192.07M194.2M225.43M347.13M197.66M
Depreciation & Amortization25.92M29.35M30.87M27.71M25.8M
EBITDA(9.28M)11.13M12.19M(6.13M)1.74M
EBITDA Margin-3.2%3.5%3.6%-2.0%0.6%
Operating Income(35.28M)(28.47M)(51.18M)(192.44M)(39.95M)
Operating Margin-12.1%-9.0%-15.1%-63.3%-13.7%
Interest Income0001.61M978K
Interest Expense861K688K2.7M00
Other Income / Expenses(769K)(1.48M)(3.26M)797K5.92M
Income Before Tax(36.05M)(29.95M)(54.44M)(191.64M)(34.03M)
Pre-Tax Margin-12.4%-9.5%-16.1%-63.1%-11.6%
Income Tax Expense(4.5M)(3.4M)(2M)(7.29M)(39K)
Net Income(31.55M)(26.55M)(52.44M)(184.35M)(33.99M)
Net Margin-10.8%-8.4%-15.5%-60.7%-11.6%
EPS (Basic)(0.82)(0.68)(1.33)(4.59)(0.83)
EPS (Diluted)(0.82)(0.68)(1.33)(4.59)(0.83)
Weighted Avg Shares38.34M39.01M39.48M40.18M40.98M
Weighted Avg Shares (Diluted)38.34M39.01M39.48M40.18M40.98M

AngioDynamics, Inc.

NASDAQ:ANGO

Intrinsic Alpha fair value

Locked

Current Price

$11.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.